{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:34Z","timestamp":1772165614956,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Metformin is the most commonly prescribed oral treatment for type 2 diabetes mellitus (T2DM) in the UK. Long-term therapy has been linked to vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      deficiency, a concern recognised for decades but not consistently addressed. In June 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) classified low vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      levels as a common adverse effect of metformin and advised clinicians to consider periodic testing in at-risk patients. Translating such regulatory advice into practice can be challenging, and the extent to which the guidance has influenced testing and diagnostic coding for vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      deficiency remains unclear. This study evaluated trends in vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      testing and deficiency coding in metformin-treated patients compared with the general population before and after the 2022 MHRA Drug Safety Update.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective quantitative analysis was conducted using Read code data from 148,000 electronic medical records across three Primary Care Networks (PCNs) in the Southwest of England. Vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      testing and deficiency coding rates were compared in patients prescribed metformin and the general population across two periods: pre-guidance (2017\u20132021) and post-guidance (2022\u20132024). Welch\u2019s t-tests were used to determine statistical significance, with\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among patients prescribed metformin, vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      testing rates rose from 34.5% (SD\u2009=\u20091.8) pre-guidance to 38.2% (SD\u2009=\u20090.4) post-guidance (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). In the general population, testing rates increased from 12.2% to 14.7% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). However, coding for vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      deficiency remained unchanged at 0.25% in the metformin group and decreased from 0.072% to 0.060% in the general population, with no statistically significant difference. The post-guidance period included only two years of data, which limits the ability to assess longer-term or comparative trends between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study demonstrated that the release of the MHRA Drug Safety Update was associated with a modest but statistically significant increase in vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      testing among patients prescribed metformin, paralleled by a smaller rise in testing within the general population. However, diagnostic coding practices did not change, suggesting limited translation of safety alerts into structured documentation. Further research is warranted to explore barriers and evaluate interventions to improve monitoring and coding compliance in primary care.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12875-025-03116-1","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:54:36Z","timestamp":1764924876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of the MHRA safety update on vitamin B12\u00a0testing and coding in metformin users: a retrospective primary care analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Ian","family":"Parsonage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"1","key":"3116_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2019","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes \u2013 global burden of disease and forecasted trends. J Epidemiol Glob Health. 2019;10(1):107. https:\/\/doi.org\/10.2991\/jegh.k.191028.001.","journal-title":"J Epidemiol Glob Health"},{"issue":"11","key":"3116_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034.","journal-title":"Diabetes Care"},{"issue":"6","key":"3116_CR3","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(6):1364\u201379. https:\/\/doi.org\/10.2337\/dc12-0413.","journal-title":"Diabetes Care"},{"issue":"4","key":"3116_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s11845-024-03634-4","volume":"193","author":"MS Al Zoubi","year":"2024","unstructured":"Al Zoubi MS, Al Kreasha R, Aqel S, Saeed A, Al-Qudimat AR, Al-Zoubi RM. Vitamin B12 deficiency in diabetic patients treated with metformin: a narrative review. Irish Journal of Medical Science (1971 -). 2024;193(4):1827\u201335. https:\/\/doi.org\/10.1007\/s11845-024-03634-4.","journal-title":"Irish Journal of Medical Science (1971 -)"},{"key":"3116_CR5","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). 2022. Available at: https:\/\/www.nice.org.uk\/guidance\/ng28 [Accessed 25 June 2025]."},{"key":"3116_CR6","unstructured":"Statista. Number of metformin prescriptions in England 2010\u20132023. 2024. Available at: https:\/\/www.statista.com\/statistics\/number-of-prescriptions-metformin-uk\/ [Accessed 25 June 2025]."},{"issue":"9131","key":"3116_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998;352(9131):854\u201365.","journal-title":"Lancet"},{"issue":"2","key":"3116_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00592-014-0661-4","volume":"52","author":"E Biemans","year":"2014","unstructured":"Biemans E, Hart HE, Rutten GEHM, Cuellar Renteria VG, Kooijman-Buiting AMJ, Beulens JWJ. Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin. Acta Diabetol. 2014;52(2):383\u201393. https:\/\/doi.org\/10.1007\/s00592-014-0661-4.","journal-title":"Acta Diabetol"},{"issue":"9","key":"3116_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2337\/diacare.23.9.1227","volume":"23","author":"WA Bauman","year":"2000","unstructured":"Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23(9):1227\u201331. https:\/\/doi.org\/10.2337\/diacare.23.9.1227.","journal-title":"Diabetes Care"},{"key":"3116_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40200-016-0250-x","author":"D Kibirige","year":"2015","unstructured":"Kibirige D, Mugenyi L, Kaddu M, Opio C, Lalitha R, Mutebi E, et al. Vitamin B12 deficiency among adult diabetic patients in Uganda: relation to glycaemic control and haemoglobin concentration. Journal of Diabetes & Metabolic Disorders. 2015. https:\/\/doi.org\/10.1186\/s40200-016-0250-x.","journal-title":"Journal of Diabetes & Metabolic Disorders"},{"issue":"sep04 1","key":"3116_CR11","doi-asserted-by":"publisher","first-page":"g5226","DOI":"10.1136\/bmj.g5226","volume":"349","author":"A Hunt","year":"2014","unstructured":"Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014;349(sep04 1):g5226\u2013g5226. https:\/\/doi.org\/10.1136\/bmj.g5226.","journal-title":"BMJ"},{"issue":"1","key":"3116_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0104-4230(11)70015-X","volume":"57","author":"M Nervo","year":"2011","unstructured":"Nervo M, Lubini A, Raimundo FV, Faulhaber GA, Leite C, Fischer LM, et al. Vitamin B12 in metformin-treated diabetic patients: a cross-sectional study in Brazil. Rev Assoc Med Bras (1992). 2011;57(1):46\u20139.","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"10","key":"3116_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1530\/ec-19-0382","volume":"8","author":"M Alvarez","year":"2019","unstructured":"Alvarez M, Sierra OR, Saavedra G, Moreno S. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study. Endocr Connect. 2019;8(10):1324\u20139. https:\/\/doi.org\/10.1530\/ec-19-0382.","journal-title":"Endocr Connect"},{"issue":"5","key":"3116_CR14","first-page":"1","volume":"26","author":"J Davies","year":"2022","unstructured":"Davies J. Metformin and vitamin B12: long overdue guidance. J Diabetes Nurs. 2022;26(5):1\u20134.","journal-title":"J Diabetes Nurs"},{"issue":"5","key":"3116_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1753-0407.12644","volume":"10","author":"AM Carracher","year":"2018","unstructured":"Carracher AM, Marathe PH, Close KL. International Diabetes Federation 2017. J Diabetes. 2018;10(5):353\u20136. https:\/\/doi.org\/10.1111\/1753-0407.12644.","journal-title":"J Diabetes"},{"issue":"7","key":"3116_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.4239\/wjd.v12.i7.916","volume":"12","author":"M Infante","year":"2021","unstructured":"Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes. 2021;12(7):916\u201331. https:\/\/doi.org\/10.4239\/wjd.v12.i7.916.","journal-title":"World J Diabetes"},{"key":"3116_CR17","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Metformin and vitamin B12 deficiency: Drug safety update. 2022. Available at: https:\/\/www.gov.uk\/drug-safety-update\/metformin-risk-of-vitamin-b12-deficiency [Accessed 25 June 2025]."},{"issue":"7","key":"3116_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-101016","volume":"15","author":"I Parsonage","year":"2025","unstructured":"Parsonage I, Wainwright D, Barratt J. Vitamin B12 deficiency in long-term metformin use and clinician awareness: a scoping review protocol. BMJ Open. 2025;15(7):e101016. https:\/\/doi.org\/10.1136\/bmjopen-2025-101016.","journal-title":"BMJ Open"},{"key":"3116_CR19","unstructured":"Office for National Statistics. Census. London: Office for National Statistics. Available from: https:\/\/www.ons.gov.uk\/census. Cited 19 Oct 2025."},{"issue":"1","key":"3116_CR20","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20x101016","volume":"4","author":"JS Treadwell","year":"2020","unstructured":"Treadwell JS, Wong G, Milburn-Curtis C, Feakins B, Greenhalgh T. GPs\u2019 understanding of the benefits and harms of treatments for long-term conditions: an online survey. BJGP Open. 2020;4(1):bjgpopen20X101016. https:\/\/doi.org\/10.3399\/bjgpopen20x101016.","journal-title":"BJGP Open"},{"issue":"7","key":"3116_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/pdi.1619","volume":"28","author":"S Qureshi","year":"2011","unstructured":"Qureshi S, Ainsworth A, Winocour P. Metformin therapy and assessment for vitamin B12 deficiency: is it necessary? Pract Diab. 2011;28(7):302\u20134. https:\/\/doi.org\/10.1002\/pdi.1619.","journal-title":"Pract Diab"},{"issue":"1","key":"3116_CR22","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpo.2022.0139","volume":"7","author":"T Jones","year":"2022","unstructured":"Jones T, Patel R, Elwenspoek MMC, Watson JC, Mann E, Alsop K, et al. Variation in laboratory testing for patients with long-term conditions: a longitudinal cohort study in UK primary care. BJGP Open. 2022;7(1):BJGPO.2022.0139. https:\/\/doi.org\/10.3399\/bjgpo.2022.0139.","journal-title":"BJGP Open"},{"key":"3116_CR23","doi-asserted-by":"publisher","unstructured":"O\u2019Sullivan JW, Stevens S, Hobbs FDR, Salisbury C, Little P, Goldacre B, Bankhead C, Aronson JK, Perera R, Heneghan C. Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. 2018. BMJ. p.k4666. Available from: https:\/\/doi.org\/10.1136\/bmj.k4666.","DOI":"10.1136\/bmj.k4666"},{"issue":"6","key":"3116_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MLR.0b013e318245a160","volume":"50","author":"SB Dusetzina","year":"2012","unstructured":"Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012;50(6):466\u201378. https:\/\/doi.org\/10.1097\/MLR.0b013e318245a160.","journal-title":"Med Care"},{"issue":"3","key":"3116_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/bmjqs-2021-013910","volume":"31","author":"RL Morrow","year":"2022","unstructured":"Morrow RL, Mintzes B, Souverein PC, De Bruin ML, Roughead EE, Lexchin J, et al. Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Qual Saf. 2022;31(3):179\u201390. https:\/\/doi.org\/10.1136\/bmjqs-2021-013910.","journal-title":"BMJ Qual Saf"},{"issue":"4","key":"3116_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.0887-378X.2004.00325.x","volume":"82","author":"T Greenhalgh","year":"2004","unstructured":"Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82(4):581\u2013629. https:\/\/doi.org\/10.1111\/j.0887-378X.2004.00325.x.","journal-title":"Milbank Q"},{"issue":"3","key":"3116_CR27","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20x101050","volume":"4","author":"JS Tulloch","year":"2020","unstructured":"Tulloch JS, Beadsworth MB, Vivancos R, Radford AD, Warner JC, Christley RM. GP coding behaviour for non-specific clinical presentations: a pilot study. BJGP Open. 2020;4(3):bjgpopen20X101050. https:\/\/doi.org\/10.3399\/bjgpopen20x101050.","journal-title":"BJGP Open"},{"issue":"7","key":"3116_CR28","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_416_19","volume":"8","author":"A Alshammari","year":"2019","unstructured":"Alshammari A, Iqbal R, Baksh I. Vitamin B12 deficiency and the knowledge and practice of physicians regarding screening for vitamin B12 deficiency among type 2 diabetic patients on metformin in selected hospitals in Riyadh, Saudi Arabia. J Fam Med Prim Care. 2019;8(7):2306. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_416_19.","journal-title":"J Fam Med Prim Care"},{"key":"3116_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-3-1","author":"AL Kitson","year":"2008","unstructured":"Kitson AL, Rycroft-Malone J, Harvey G, McCormack B, Seers K, Titchen A. Evaluating the successful implementation of evidence into practice using the PARiHS framework: theoretical and practical challenges. Implement Sci. 2008. https:\/\/doi.org\/10.1186\/1748-5908-3-1.","journal-title":"Implement Sci"},{"issue":"9391","key":"3116_CR30","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/s0140-6736(03)14546-1","volume":"362","author":"R Grol","year":"2003","unstructured":"Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients\u2019 care. Lancet. 2003;362(9391):1225\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(03)14546-1.","journal-title":"Lancet"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03116-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-03116-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03116-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:54:25Z","timestamp":1771595665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12875-025-03116-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3116"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-03116-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7306714\/v1","asserted-by":"object"}]},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project is part of a wider thesis as part of a Post Doctoral award.The study was conducted in accordance with the ethical principles of the Declaration of Helsinki (2013). Ethical approval was granted by the University of Bath Research Ethics Committee (reference 1759-7102) and the Health Research Authority (IRAS ID 336490), with the University of Bath acting as study sponsor. All methods were performed in accordance with relevant institutional and national research guidelines and regulations. The study utilised anonymised, aggregated data extracted from electronic medical records; no identifiable personal data were collected, and individual patient consent was therefore not required.Informed consent to collect the data was gained from the Clinical Director of each participating organisation. As no personal identifiable information was collected and no electronic medical notes were individually accessed, individual consent was not necessary. This position was reviewed and approved by both the University of Bath Research Ethics Committee (reference 1759-7102) and the Health Research Authority (IRAS ID 336490), who confirmed that informed consent from individual participants was not necessary under national research governance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}